rs762368691
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000080.4(CHRNE):c.130dupG(p.Glu44fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000446 in 1,613,646 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000042 ( 0 hom. )
Consequence
CHRNE
NM_000080.4 frameshift
NM_000080.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -1.26
Genes affected
CHRNE (HGNC:1966): (cholinergic receptor nicotinic epsilon subunit) Acetylcholine receptors at mature mammalian neuromuscular junctions are pentameric protein complexes composed of four subunits in the ratio of two alpha subunits to one beta, one epsilon, and one delta subunit. The acetylcholine receptor changes subunit composition shortly after birth when the epsilon subunit replaces the gamma subunit seen in embryonic receptors. Mutations in the epsilon subunit are associated with congenital myasthenic syndrome. [provided by RefSeq, Sep 2009]
C17orf107 (HGNC:37238): (chromosome 17 open reading frame 107)
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 17-4902679-T-TC is Pathogenic according to our data. Variant chr17-4902679-T-TC is described in ClinVar as [Pathogenic]. Clinvar id is 243030.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CHRNE | NM_000080.4 | c.130dupG | p.Glu44fs | frameshift_variant | 2/12 | ENST00000649488.2 | NP_000071.1 | |
C17orf107 | NM_001145536.2 | c.*2149dupC | 3_prime_UTR_variant | 3/3 | ENST00000381365.4 | NP_001139008.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CHRNE | ENST00000649488.2 | c.130dupG | p.Glu44fs | frameshift_variant | 2/12 | NM_000080.4 | ENSP00000497829.1 | |||
C17orf107 | ENST00000381365.4 | c.*2149dupC | 3_prime_UTR_variant | 3/3 | 2 | NM_001145536.2 | ENSP00000370770.3 | |||
CHRNE | ENST00000649830.1 | c.-804dupG | 5_prime_UTR_variant | 2/11 | ENSP00000496907.1 | |||||
CHRNE | ENST00000575637.1 | n.-50dupG | upstream_gene_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000725 AC: 11AN: 151772Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
151772
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000103 AC: 26AN: 251458Hom.: 0 AF XY: 0.000110 AC XY: 15AN XY: 135916
GnomAD3 exomes
AF:
AC:
26
AN:
251458
Hom.:
AF XY:
AC XY:
15
AN XY:
135916
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000417 AC: 61AN: 1461874Hom.: 0 Cov.: 35 AF XY: 0.0000399 AC XY: 29AN XY: 727236
GnomAD4 exome
AF:
AC:
61
AN:
1461874
Hom.:
Cov.:
35
AF XY:
AC XY:
29
AN XY:
727236
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000725 AC: 11AN: 151772Hom.: 0 Cov.: 32 AF XY: 0.0000674 AC XY: 5AN XY: 74138
GnomAD4 genome
AF:
AC:
11
AN:
151772
Hom.:
Cov.:
32
AF XY:
AC XY:
5
AN XY:
74138
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:12Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Congenital myasthenic syndrome 4C;C4225369:Congenital myasthenic syndrome 4B;C4225413:Congenital myasthenic syndrome 4A Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Nov 27, 2021 | A homozygous single base pair duplication in exon 2 of the CHRNE gene that results in a frameshift and premature truncation of the protein 3 amino acids down stream to codon 44 was detected. This variant has not been reported in the 1000 genomes database and has a minor allele frequency of 0.007% in the gnomAD. The observed variation has previously been reported in patients affected with congenital myasthenic syndrome. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 26, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Mar 11, 2022 | PVS1, PM2, PM3 - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 16, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 06, 2021 | Published functional studies demonstrate impaired a-bgt binding to the acetylcholine receptor (Ohno et al., 1998); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 9708546, 20301347, 29383513, 31773638) - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 04, 2017 | - - |
Congenital myasthenic syndrome Pathogenic:2Other:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 17, 2018 | The p.Glu44GlyfsX3 variant in CHRNE is a well-established pathogenic variant and has been reported in >20 Spanish and Portuguese individuals with congenital mya sthenic syndrome (Ohno 1998, Mihaylova 2010, Natera-de Benito 2017, Estephan 201 8). It has been reported as Pathogenic in ClinVar (Variation ID 243030), and has been identified in 0.06% (20/33580) of Latino chromosomes by the Genome Aggrega tion Database (gnomAD, http://gnomad.broadinstitute.org). Although this variant has been seen in the general population, its frequency is low enough to be consi stent with a recessive carrier frequency. This variant is predicted to cause a f rameshift, which alters the protein?s amino acid sequence beginning at position 44 and leads to a premature termination codon 3 amino acids downstream. This alt eration is then predicted to lead to a truncated or absent protein. In summary, this variant meets criteria to be classified as pathogenic for congenital myasth enic syndrome in an autosomal recessive manner. ACMG/AMP Criteria applied: PVS1, PM3_VeryStrong, PS3_Supporting. - |
Congenital myasthenic syndrome 4A Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change creates a premature translational stop signal (p.Glu44Glyfs*3) in the CHRNE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CHRNE are known to be pathogenic (PMID: 22678886). This variant is present in population databases (rs762368691, gnomAD 0.06%). This premature translational stop signal has been observed in individuals with autosomal recessive congenital myasthenic syndrome (PMID: 9708546). This variant is also known as epsilon70insG. ClinVar contains an entry for this variant (Variation ID: 243030). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Myasthenic syndrome, slow-channel congenital Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | DASA | Jan 05, 2022 | The c.130dupG;p.(Glu44Glyfs*3) is a null frameshift variant (NMD) in the CHRNE gene and predicts alteration of the nonsense-mediate decay - NMD is present in a relevantexon to the transcript -PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 243030; PMID: 20301347; 9708546; 22678886; 29383513;29054425; 20562457; 9708546PS4. The variant is present at low allele frequencies population databases (rs762368691– gnomAD 0.007248%; ABraOM 0.000854 frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Glu44Glyfs*3) was detected in trans with a pathogenic variant (PMID: 29383513, 29054425) - PM3. The variant co-segregated with disease in multiple affected family members (PMID: 29383513) - PP1_moderate. In summary, the currently available evidence indicates that the variant is pathogenic. - |
Abnormality of the musculature Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Kariminejad - Najmabadi Pathology & Genetics Center | Jul 10, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at